<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374085</url>
  </required_header>
  <id_info>
    <org_study_id>CC-92480-MM-001</org_study_id>
    <secondary_id>U1111-1205-3650</secondary_id>
    <secondary_id>2017-001236-19</secondary_id>
    <nct_id>NCT03374085</nct_id>
  </id_info>
  <brief_title>A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, international, Phase 1 study to assess the safety, PK/PD
      and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with RRMM.

      RRMM patient previously treated with at least 3 prior regimens including lenalidomide or
      pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">March 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>From enrollment until at least 28 days after completion of study treatment</time_frame>
    <description>Number of participants with AEs (Type, frequency, seriousness, severity and relationship of AEs to CC-92480 and dexamethasone; changes from baseline in clinically-relevant physical findings, vital signs, selected laboratory analytes, ECGs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- AUC</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- Cmax</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Maximal plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- Tmax</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Time to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- t1/2</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Terminal-phase elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- CL/F</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Apparent total clearance of the drug from plasma after oral administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics- Vz/F</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>Apparent volume of distribution during terminal phase after non-intravenous administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>The highest dose of CC-92480 in combination with dexamethasone associated acceptable safety and tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best response ≥ partial response (PR), according to the IMWG Uniform Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from 1st dose of CC-92480 to the first documentation of response ≥ PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from the first documentation of response (≥ PR) to the first documentation of PD or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Time from 1st dose of CC-92480 to the first occurrence of disease progression or death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Administration of CC-92480 and Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of CC-92480 in combination with a fixed dose of dexamethasone administered according to two different dosing schedules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-92480</intervention_name>
    <description>CC-92480</description>
    <arm_group_label>Administration of CC-92480 and Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Administration of CC-92480 and Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥ 18 years of age and ECOG performance status score of 0, 1 or 2

          2. All subjects must have:

               1. received at least 3 prior anti-myeloma regimens including at least 2 consecutive
                  cycles of lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid
                  and a CD38 antibody (note: induction with or without bone marrow transplant and
                  with or without maintenance therapy is considered one regimen),

               2. documented disease progression on or within 60 days from the last dose of their
                  last myeloma therapy,

               3. in addition to criteria above (a and b), subjects enrolled in Part 2 must have
                  disease refractory to an immunomodulatory agent (lenalidomide and/or
                  pomalidomide), a glucocorticoid, a proteasome inhibitor, and a CD38 antibody.
                  Refractory is defined as disease that is nonresponsive on therapy (failure to
                  achieve minimal response or development of progressive disease), or progresses
                  within 60 days of last dose.

          3. Subjects must have adequate bone marrow, renal, liver, and cardiac function.

          4. Females of childbearing potential (FCBP) and male subjects must agree with the
             pregnancy prevention plan.

        Exclusion Criteria:

          1. Subject has a significant medical condition, laboratory abnormality, or psychiatric
             illness that would prevent the subject from participating in the study.

          2. Subject has non- or oligosecretory multiple myeloma.

          3. Subject is unable or unwilling to undergo protocol required venous thromboembolism
             (VTE) prophylaxis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsvetan Biyukov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center The University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol Can Ruti</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octobre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine</name>
      <address>
        <city>Oxford</city>
        <zip>0X3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>CC-92480</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

